Long-Acting ART Is Here. How Do We Make It Work for Our Patients?

Injectable HIV interventions are a game-changing new option for people dealing with pill fatigue, but there are implementation challenges for clinicians to consider.

American teens

This Week in HIV Research: We Need to Better Serve Our Teens

April 8, 2021: PrEP “contemplation” and uptake among adolescents; adolescent perception of HIV risk; HIV diagnosis rates among transgender people; PrEP and HIV incidence in Scotland.

By Barbara Jungwirth and Myles Helfand
photo of David Alain Wohl, M.D., as he recaps research from CROI 2021

Sleep and Diet: Don’t Underestimate Their Importance for People Living With HIV

David Alain Wohl, M.D., on new findings from CROI 2021 that help us better understand the connections between sleep, diet, and quality of life among people living with HIV.

By David Alain Wohl, M.D.
The main entrance to Grady Health System in downtown Atlanta, Georgia

How Can Clinics Become Safer Places for Transgender Women to Access PrEP?

Researchers recommend PrEP programs be linked to a gender-affirming care clinic, to build trust and retain patients in care.

By Mathew Rodriguez

Our Newest Posts

empty shot
Adverse Events, Comorbidities, and HIV

This Week in HIV Research: The Complexities of Alcohol and Substance Use

April 15, 2021: Alcohol and neurocognitive impairment; using hair analysis to measure substance use; integrase inhibitors' impact on verbal learning; hepatocellular carcinoma trends among PLWH.

By Barbara Jungwirth and Myles Helfand
Sundararajan Team and TBA
HIV Care and Services Outside the US

Traditional Healers Offer a Culturally Competent Approach to HIV Testing Gaps

In sub-Saharan Africa, herbalists and spiritual healers are working closely with researchers to help reduce HIV transmission in rural communities.

By Terri Wilder, M.S.W.
David Alain Wohl recaps CROI 2021 research during a video interview
Providing Quality HIV Care

CROI 2021 Highlights: New HIV Research With Clinical Impact

Here's a walkthrough of some of the most compelling stories coming out of the year's biggest HIV science meeting to date.

By Myles Helfand
thumbnail CITY Jeremy Tjhung-25033
Adverse Events, Comorbidities, and HIV

Most Cancer Drug Trials Still Exclude People With HIV. That’s Both Unfounded and Dangerous.

Helping my longtime friend Jeremy find such trials alerted me to this ongoing problem—which will only be reversed if patients, doctors, and trial reviewers keep pushing back on Pharma.

By Tim Murphy
clinical trial
HIV Epidemiology

Clinical Trial Data Needs to Reflect the Demographics of HIV, Say Activists

A recent analysis conducted by the AIDS Treatment Activists Coalition revealed that, among HIV drug trial participants, data specific to race and sex were dramatically underreported.

By Terri Wilder, M.S.W.
HIV Prevention Methods

HIV Data Bites: Recent Advances in Broadly Neutralizing Antibodies for HIV Prevention

While findings from the high-profile AMP studies have excited scientists, they’re only one of a wide range of bNAb avenues currently being pursued.

By Michael Broder

Refer your clients and patients to TheBody, TheBodyPro's sibling site for people living with or affected by HIV. TheBody delivers vital information, news, support, and personal perspectives on HIV and related issues.